AllRock Bio $50M Series A: Pipeline Trigger

🚀 Battle Card: AllRock Bio

• Catherine Pearce, DHSc, MBA, Co-Founder & CEO 📧 cpearce@allrockbio.com

• This AllRock Bio sales trigger brings fresh funding to support ROC-101’s Phase 2 launch → Source

• Advancing ROC-101 efficiently into Phase 2 trials

• Scaling clinical operations under tight timelines

• Primary: Clinical Trial Management Solutions → Streamline Phase 2 workflows

• Expansion: Regulatory Affairs Platforms → Accelerate FDA submissions

• HQ: Natick, MA

• Employees: ≈ 75

• Rev: ≈ $0

• Website: allrockbio.com

🤼 Competitive Intel

• United Therapeutics — PAH therapies
• Unique edge: Market leader for PAH drugs
• Evaluated by Clinical Ops & CMO

• Actelion (Janssen) — PAH & fibrosis pipeline
• Unique edge: Deep pipeline and M&A support
• Evaluated by CEO’s strategic R&D team

• Bayer — Fibrosis therapeutics
• Unique edge: Global distribution network
• Evaluated by COO for scale

• FibroGen — Anti-fibrotic drugs
• Unique edge: Phase 3 programs nearing readout
• Evaluated by Clinical Ops for comparator data

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑NewsletterForLeads❑
OFFER_BRIEF   = ❑Streamlined clinical trial workflows❑
PROOF_METRIC  = ❑50% faster phase transitions❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Catherine
COMPANY     = AllRock Bio
DEPT        = Clinical Operations
SIZE        = 75
BOTTLENECK  = Scaling clinical ops under tight timelines
EVENT       = Series A funding
DETAIL      = AllRock Bio Announces $50M Series A Round
PAIN        = Advancing ROC-101 efficiently into Phase 2 trials
SRC         = https://vcnewsdaily.com/allrock-bio/venture-capital-funding/kzdwhxzvgl
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = TBD
EMP_EST     = 75
REV_EST     = ≈ $0M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 75-person Clinical Operations

Catherine—noticed your Clinical Operations team is ≈ 75.

That’s when Scaling clinical ops under tight timelines slows growth.

We helped ≈ TBD fix this with Streamlined clinical trial workflows.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about AllRock Bio Announces $50M Series A Round — Advancing ROC-101 efficiently into Phase 2 trials.  
Streamlined clinical trial workflows. 50% faster phase transitions.  
Quick chat?